Scilex Approved A Resolution To Authorize Management To Explore Ways In Which To Maximize Value Of Semnur Pharmaceuticals And SP-102, Including By Way Of Conducting A Spin-off, Merger, Dividend, Reclassification Or Other Similar Transaction.

Author: Benzinga Newsdesk | June 17, 2024 03:38pm

- SEC Filing

 

On June 17, 2024, the Board of Directors of Scilex Holding Company (the "Company") approved a resolution to authorize management to explore ways in which to maximize the value of Semnur Pharmaceuticals, Inc. ("Semnur"), the Company's wholly owned subsidiary, and SP-102 (SEMDEXA™), the product candidate held by Semnur, for the Company and its stockholders, including by way of conducting a spin-off, merger, dividend, reclassification or other similar transaction.

Posted In: SCLX